I
UC San Diego Technology Transfer Advisory Committee
The UC San Diego Technology Transfer Advisory Committee (TTAC) is responsible for general oversight of the university’s
technology transfer program. This standing committee is appointed and chaired by the vice chancellor for research. It meets
quarterly to assess UC San Diego’s technology transfer practices and guide the overall direction of the program.
Arthur Ellis (Chair)
Vice Chancellor, Research
Steve Kay
Dean, Division of Biological Sciences
Amy Alexander
Associate Professor, Visual Arts
Michael Kelner
Professor, Pathology
Michael Burkart
Professor, Chemistry and Biochemistry
William Kuperman
Professor, Scripps Institution of
Oceanography—Marine Physical
Laboratory
Linda Dale
Assistant Vice Chancellor, Office of
Contract and Grant Administration
Michael David
Professor, Biology
Jane Moores
Assistant Vice Chancellor,
Technology Transfer
Rosibel Ochoa
Executive Director, William J. von Liebig
Center—Jacobs School of Engineering
Geert Schmid-Schoenbein
Professor, Bioengineering
Frieder Seible
Dean, Jacobs School of Engineering
Robert Sullivan
Dean, Rady School of Management
Adriene Jenik
Professor, Visual Arts
UC San Diego Industry Technology Transfer Advisory Committee
The UC San Diego Industry Technology Transfer Advisory Committee (I-TTAC) provides guidance, from an industry
perspective, on university technology transfer and strengthens ties with our industry partners.
Julia Brown
Member of board of directors:
CONNECT, Labopharm, Inc., MediQuest
Therapeutics, Inc., and Targacept, Inc.
Scott Minick
President and CEO, BIND Biosciences
(since January 2010)
Venture Partner (Managing Director
during FY2009), ARCH Venture Partners
Bob Slapin
Executive Director, San Diego Software
Industry Council
2009 Annual Report
Message from the
Assistant Vice Chancellor
T
echnology transfer plays a pivotal role in delivering new
innovations to commercial markets and contributing to
a vibrant economy. Despite a pervasive downturn in the
global economy, UC San Diego’s Technology Transfer Office (TTO)
continues to leverage its resources by placing university technology
into the capable hands of established and entrepreneurial
businesses.
Last fiscal year, we managed innovation disclosures, patenting,
and marketing activities for campus constituents and licensed
technologies to both existing and start-up companies. Furthermore,
for the first time since its inception, TTO surpassed the fourhundred mark in the number of innovation disclosures received and
processed in a fiscal year period.
In addition, we continued to work with our business partners to
weather a tough economic climate. Our investment of time and
energy helps to yield products and technologies that have great
potential to fuel the future growth of our region and contribute to
the public good. To demonstrate this point, we added cumulative
information in this report regarding the number of start-ups formed
in the last decade using licensed UC San Diego technology.
To further enhance our relationships with corporate partners, an
Industry Technology Transfer Advisory Committee was formed
to serve as an interface between the university and the business
sector. The TTO is working with this committee to explore new
and even more effective mechanisms to translate academic
technologies into broader use by commercial entities. Each member
was selected for their expertise in business areas that TTO targets
for potential partnering opportunities.
In calendar year 2010, the university will celebrate its 50th
Anniversary. In the short time since its founding in 1960, UC San
Diego has been hailed for its academic and scientific achievements.
While our technology transfer program is even younger by
comparison, TTO has advanced rapidly in its mission to transfer
technology by continuing to improve services and by cultivating
relationships with campus and corporate partners. Reflecting the
university’s vision, our licensing activities in San Diego and beyond
have local impact, national influence, and global reach.
In this report we share our ongoing efforts to illustrate how university
research translates into new jobs, technologies, products, and
treatments that make our world a better place.
Sincerely,
Jane C. Moores, Ph.D.
Assistant Vice Chancellor, Technology Transfer
Technology Transfer Office
Otonomy, Inc.
T
he genesis of Otonomy was sparked by a trip to the
emergency room in January 2008. Jay Lichter, a busy
business executive and entrepreneur, had an otic (inner ear)
disorder that resulted in partial hearing loss six months previously.
However, on this day, it was worse than usual. Suffering from an
extended bout of vertigo, Lichter was scheduled for an audiology
exam to be followed by a visit to an ear, nose, and throat (ENT)
doctor. The ENT specialist was Dr. Jeffrey Harris, Chief of the
Division of Otolaryngology, Head and Neck Surgery at UC San
Diego, who diagnosed Lichter with Ménière’s disease, an inner ear
disorder that affects hearing and balance and has no known or
approved drug treatment.
The conversation between the two men evolved into a business
discussion exploring alternate means of treating simple otic
disorders—like hearing loss—and led to Lichter asking Harris about
ideas for starting a new company. Lichter and Harris eventually
arranged a meeting with Allen Ryan, professor of surgery at UC San
Diego. Jointly the three men founded Otonomy, Incorporated and
approached UC San Diego’s Technology Transfer Office to discuss
licensing options in May 2008. The trio subsequently signed a
license agreement in November 2008.
As cofounders and leaders on Otonomy's scientific advisory board,
Harris and Ryan collaborated with the Otonomy science team. By
the end of the fourth quarter of 2008, the group had developed
the company’s first compound and had determined dosage
proportionality in an animal model.
According to Lichter, “Our first product is a steroid to treat Ménière’s
disease. We have a second product in the making that will be an
antibiotic for middle ear infections.”
But Otonomy is not just about compound therapies. The company
also devised an innovative delivery mechanism. Current conventions
involve physicians injecting a solution into the middle ear, where
it remains for barely an hour, then drains out. Otonomy’s delivery
mechanism incorporates hydrogel technology. Using a small
needle, physicians deliver the compound into the ear as a liquid that
thickens when it reaches body temperature. The resulting pudding-
2
like substance provides sustained release of the compound for
weeks and even months.
With its therapeutic approaches and innovative drug-delivery
technologies, Otonomy is focused on treatments for several
otic disorders: age-related hearing loss, noise-related hearing
loss, Ménière’s disease, otitis media, tinnitus, and sudden and
sensorineural hearing loss. While not life-threatening, these
conditions decrease the quality of life for nearly 30 million
Americans. The available solutions have been ineffective: oral
antibiotics that treat a localized problem too broadly or direct-area
solutions that drip down the Eustachian tube too quickly.
Future possibilities for treatment could reduce the risks of surgically
implanted ear tubes in children. The new sustained-release gel
could be injected during surgery for a one-time treatment that
lasts for a week. Additionally, with a more effective direct-delivery
mechanism, the new treatments may potentially reduce the use of
resistance-causing oral antibiotics.
2009 Annual Report
Neuropore Therapies, Inc.
I
n 2007, UC San Diego researcher Dr. Eliezer Masliah (professor,
neuroscience and pathology) announced a breakthrough
discovery in the area of neurodegenerative disorders. The
discovery resulted from a collaborative effort between Masliah, Igor
Tsigelny (researcher, neurosciences and San Diego Supercomputer
Center), and Wolf Wrasidlo (researcher, Moores UCSD Cancer
Center) and provides a new approach to the treatment of
individuals diagnosed with Parkinson’s disease (PD), Alzheimer’s
disease (AD), and other similar conditions.
The discovery was licensed the following year by a newly formed
start-up venture—Neuropore Therapies, Incorporated. Formed in
2008, Neuropore advanced Masliah’s research and is developing
and testing compounds that block the protein aggregates
associated with these adverse neurological conditions.
The basis of Masliah’s research is centered on the premise
that protein aggregates form abnormally in the brains of PD
and AD patients, causing a neurologically toxic condition. More
specifically, the toxic aggregates—known as oligomers—penetrate
an individual’s brain-cell membranes, causing impaired neuronal
communication and functioning.
Neuropore Therapies’ approach is to develop proprietary smallmolecule compounds that interfere with the formation of these
alpha-synuclein (PD) and amyloid-beta (AD) oligomers. The
compounds may offer promising alternatives to a medical
community that has been able to offer only palliative treatments.
Currently, PD affects about 6.3 million people and AD affects
approximately 35 million people globally. The incidence of both
diseases is expected to grow significantly as the population ages.
According to Masliah, who serves as a scientific and clinical
advisor for Neuropore Therapies, the compounds will be ready for
preclinical testing in 2010 and for phase I trials in the next couple
of years.
An -synuclein pore model of
Parkinson’s disease.
3
Technology Transfer Office
Products from
University Innovation
I
n FY2009 more than 60 companies and organizations offered over 200 products derived from UC San Diego innovations. The companies
represent industry segments in biotechnology, consumer food additives, data storage, diagnostics, engineering equipment, genomics,
pharmaceuticals, publishing, raw chemicals, research reagents and tools, software, structural materials, and wireless communications.
Our corporate partners play a major role in developing and advancing university innovation into commercial products. Some of the UCSD
innovations were components of a commercial product and others were stand-alone materials, software, images, or therapeutics.
1
2
3
4
5
6
7
8
9
10
11
12
(1) Cloud Condensation Nuclei (CCN) Counter is sold by Droplet Measurement Technologies to measure atmospheric particles. (2) The
Ortiva Wireless mobile Video Optimization Gateway (mVOG™) is a server–based system that optimizes multimedia content for reliable
delivery to mobile devices. (3) Fluorescent proteins are part of assay kits sold by several research reagent companies. (4) Pentosan
polysulphate treats interstitial cystitis and is sold as Elmiron® by Ortho-McNeil-Janssen Pharmaceuticals, Inc. (5) ERBITUX® (cetuximab)
is sold by ImClone Systems (a wholly-owned subsidiary of Eli Lilly and Company) and Bristol-Myers Squibb Company for the treatment
of colorectal cancer and head and neck cancer. (6) CytoTrap is an assay used to study protein-to-protein interactions and is sold by
Agilent Technologies-Stratagene Products. (7) Nirvana® SRB® Data Sharing, Metadata, and Advanced Data Management for Complex
Environments is sold by Nirvana (a division of General Atomics). (8) Chromatin Assembly Kit is a research kit marketed by Active Motif.
(9) Promega bioluminescent reagents are used worldwide for life science research and pharmaceutical discovery. (10) Senomyx, Inc.
has product discovery and development collaborations with global food, beverage, and ingredient supply companies, some of which are
currently marketing products that contain Senomyx’s flavor ingredients. (11) Marine-controlled source EM (CSEM) instrument surveys
the seafloor for potential oil deposits. (12) Walrus Internet Graphic that shows network topology has been licensed to several publishers.
4
2009 Annual Report
Start-ups
U
C San Diego continues to be a magnet for stellar science and entrepreneurial culture; the creative talent on the campus triggers
the growth of new businesses in our region. Many current and former faculty members, staff members, alumni, and students
have ventured forth to start new companies. While university affiliates have been credited with forming more than 200 start-up
companies, the Technology Transfer Office specifically tracks start-up companies with formal license agreements with the university for
foundational technology, which number more than 130. The chart below illustrates the start-up activity for the Technology Transfer Office
over the last decade. These companies were formed with one or more technologies licensed from TTO.
In FY2009, seven start-ups were formed with licensed university technology, compared to fourteen start-ups formed in the prior fiscal year.
The decrease in the number of start-ups can be attributed to the collapse in the financial markets during this period. Venture firms and other
investor groups significantly retreated from funding new businesses, preserving their capital in anticipation of an economic recovery. Two
start-ups from the FY2009 group are highlighted in the preceding section.
Start-ups with Licensed UCSD Technology FY2000–2009
8
Biomedical/Life Science
5
8
Engineering/Software/Physical Science
4
7
6
6
7
10
9
5
4
7
6
3
2
3
3
2
2
Total
7
11
10
8
9
15
17
9
14
7
Year
00
01
02
03
04
05
06
07
08
09
5
6
7
2009 Results
Technology Transfer Agreements
699 713
In FY2009, total agreement activity decreased to 697
compared to 796 during FY2008. The agreements comprised
licenses, options, outgoing material transfers, confidentiality,
letters of intent, and other administrative agreements. Much of
the decrease can be attributed to reduced numbers of outgoing
material transfer agreements.
576 592
747 758
796
697
626
489
The licensing activity for inventions was similar to last year:
42 invention licenses in FY2009 compared to 41 in FY2008.
Copyright licensing decreased to 23 in FY2009 from 41 in FY2008.
00
01
02
03
04
05
06
07
08
09
License Agreements for Inventions and Copyrights FY2000–2009
Copyrights/Trademarks
Inventions
56
54
49
41
41
42
41 41
34
29
28
23
23
18
12
23
22
17
15
6
8
Total
47
46
51
41
56
71
71
85
82
65
Year
00
01
02
03
04
05
06
07
08
09
Patents
Patent prosecution and protection of UC San Diego innovations continues to be a major component of our activities. In FY2009,
286 patent applications were filed, of which 225 were U.S. provisional and nonprovisional applications. The total number of
filings in FY2009 increased from 265 patents filed in FY2008. Since FY2002, the campus has filed over 200 patent applications
each fiscal year.
In FY2009, total issued patents decreased to 151 patents, as compared to 161 patents in FY2008. The number of U.S. patents
issued increased to 54 patents in FY2009, as compared to 45 U.S. patents issued in FY2008. On average, it takes from three to
five years for a U.S. patent to issue from the time an application is first examined at the U.S. Patent and Trademark Office.
Patent Activities FY2000–2009
PATENTS FILED
U.S. Provisional
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
TOTAL
55
74
75
127
144
133
147
142
127
152
1,176
U.S. Nonprovisional
87
76
86
45
44
39
35
65
85
73
635
International
22
40
41
69
94
67
89
60
53
61
596
164
190
202
241
282
239
271
267
265
286
2,407
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
TOTAL
58
59
42
51
50
60
44
64
45
54
527
Total Filed
PATENTS ISSUED
U.S.
Foreign
Total Issued
33
36
39
69
79
87
148
62
116
97
766
91
95
81
120
129
147
192
126
161
151
1,293
Mandatory Distributions
The Technology Transfer Office distributed approximately $15.1 million of intellectual property income in FY2009, compared
to $14.8 million in FY2008. Distributions were made to inventors/authors, joint co-owners of IP, participating academic units
for research support, the campus fund, and the UC General Fund in accordance with UC policies and UC San Diego campus
guidelines. Invention and copyright income distributions are based on income received in the prior fiscal year (accrual basis).
Material Transfer Agreement (MTA) income distribution is based on income received in the same fiscal year (cash basis).
Mandatory Distributions of IP Management Income FY2000–2009 (In Thousands)
Inventor/Author Share
Joint Titleholders Share
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
TOTAL
$1,598
$2,155
$2,098
$4,054
$2,654
$3,727
$6,192
$8,667
$8,605
$9,553
$49,303
$60
$197
$633
$304
$295
$77
$393
$127
$398
$432
$2,916
Research Labs/HAU*/Dept. Share
$980
$929
$1,990
$1,271
$1,126
$1,215
$1,747
$2,501
$2,332
$2,516
$16,606
UC General Fund Share†
$730
($412)
$1,519
($1,219)
$1,007
$2,657
$3,382
$2,612
$3,470
$2,569
$16,318
$3,368
$2,869
$6,240
$4,410
$5,082
$7,676
$11,714
$13,907
$14,806
$15,070
$85,142
Total Distributions
*Home Academic Unit
† FY01 and FY03 shows credit due to extraordinary legal expenses; formerly called State General Fund.
Some totals may change from year to year due to post-closing adjustments.
9
Intellectual Property Disclosures
The number of invention and copyright disclosures reported to our office rose to 428 during FY2009, compared to 364
disclosures during FY2008. This is the first time that the campus surpassed the 400 mark in the number of disclosures received
and processed in a fiscal year period. Since FY2002 the campus has achieved more than 300 disclosures per fiscal year. At the
end of FY2009, the campus had more than 2,600 innovations in its portfolio.
Total Intellectual Property Disclosures FY2000–2009
396
Copyrights
Inventions
333
294
265
330
310
290
288
255
194
56
41
28
16
44
40
35
26
32
Total
235
281
311
322
314
334
345
373
364
428
Year
00
01
02
03
04
05
06
07
08
09
$30.8
Intellectual Property Income
FY2000–2009 (In Millions)
Intellectual property income includes
patent cost reimbursements and
payments of fees and royalties from
inventions, copyrights, and tangible
research materials.
$27.1
$26.7 $26.2
$21.7
$17.0
01
$15.1
$10.7
$9.0 $8.4
00
10
34
02
03
04
05
06
07
08
09
Income
In FY2009, intellectual property income was approximately $27.1 million, compared to approximately $30.9 million generated
in FY2008. Income included nearly $22.2 million in license fees and royalties, which was down $460,000 from the previous
year; $491,000 from fees for copyrights and transfers of tangible research materials, which was down $412,000 compared to
the previous year; and approximately $4.4 million in patent cost reimbursement, down by about $2.9 million compared to the
previous year.
Operating Expenses, Reimbursable Expenses, and Distributions
The Technology Transfer Office incurred outlays of $12 million in FY2009, as compared to $13.4 million in the previous year. The
decrease was attributed to lower patent prosecution costs of $6.3 million in FY2009, versus $7.1 million in the previous year and
lower contributions to the UC General Fund for $2.6 million in FY2009, as compared to $3.5 million in the previous year. Campus
operations costs were up slightly to $3.1 million in FY2009, compared to $2.7 million in the previous year.
Income and Expenses FY2000–2009 (In Thousands)
The income and expense tables below provide detail on the sources of revenue received and expenses incurred in
managing university technology.
INCOME
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
TOTAL
Invention
$5,477
$5,627
$7,240
$6,368
$11,473
$15,496
$21,842
$21,423
$22,694
$22,235
$139,875
Copyright
$84
$46
$203
$157
$314
$214
$311
$219
$317
$236
$2,101
$647
$595
$1,123
$474
$405
$578
$310
$329
$586
$255
$5,302
$2,815
$2,032
$2,899
$3,678
$2,896
$5,396
$4,234
$4,080
$7,261
$4,397
$39,688
$33
$56
$5,552
–
–
–
$1
$193
$23
–
$5,858
$9,056
$8,356
$17,017
$10,677
$15,088
$21,684
$26,698
$26,244
$30,881
$27,123
$192,824
Tangible Research
Materials
Legal Cost
Reimbursement
Extraordinary
Income*
Total Income
EXPENSE
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
TOTAL
$3,503
$3,104
$3,833
$4,029
$4,645
$6,132
$6,161
$6,336
$7,126
$6,263
$51,134
$8
$5
$1
$3
–
$4
–
–
–
–
$20
$1,214
$1,386
$1,696
$1,981
$2,263
$2,272
$2,691
$2,732
$2,738
$3,077
$22,052
UCOP & OTT
Assessment
$438
$603
$862
$902
$877
$892
$879
$461
$65
$65
$6,044
Extraordinary
Expenses†
$221
$3,916
$2,993
$6,567
$2,789
$459‡
$57
$205
$18
$3
$17,228
UC General
Fund**
$730
($412)
$1,519
($1,219)
$1,007
$2,657
$3,382
$2,612
$3,471
$2,569
$16,316
Total Expense
$6,114
$8,602
$10,904
$12,263
$11,581
$12,416
$13,170
$12,346
$13,418
$11,977
$112,791
NET INCOME
$2,942
($246)
$6,113
($1,586)
$3,507
$9,268
$13,528
$13,898
$17,463
$15,146
$80,033
Patent
Prosecution
Copyright
Campus
Operations
*Extraordinary income includes nonrecurring items such as legal settlements and/or one-time payments.
† Extraordinary expenses includes unbudgeted expenses for litigation and settlement.
‡ FY2005 extraordinary expenses increased by $201,000 from prior reports due to post-closing adjustments.
**UC General Fund was previously called State General Fund.
Some totals may change from year to year due to post-closing adjustments.
11
Technology Transfer Office
Community Outreach
and Partnering Events
T
he Technology Transfer Office attends, supports, participates
in, or organizes various events throughout the year to promote
technology transfer and university research.
July 08
CONNECT Venture Roundtable*
4th Modern Drug Discovery and Development Summit—
University/Industry Partnering*
CONNECT Frontiers in Science—Planning Session*
Licensing Executive Society (LES) Annual Meeting—Orlando, FL
Global CONNECT—South Korea Economic Development
University Licensing: Opportunities and Issues—UCSD Department
Technology Exchange*
Tech Trek, American Association of University Women—Science and Math
Outreach Program for Middle School Girls*
Technology Showcase at the von Liebig Center
Panel Discussion: Explaining University Technology Transfer to Industry*
CONNECT Frontiers in Science and Technology—Protein Networks
in Cancer
August 08
of Bioengineering*
Consultants Forum Annual Meeting
BIOCOM Investor Conference
Cleantech Initiative Awards
November 08
Technology Transfer Presentation—UCSD Department of Bioengineering*
CommNexus San Diego
Innovators Roundtable Meeting—Life Sciences Presentations*
Translational Oncology Symposium—Moores UCSD Cancer Center
Entrepreneurial Seminar—von Liebig Center
CONNECT Industry Advisory Committee*
4th Annual SABPA Pacific Forum on Life Science Alliances
Licensing Executive Society (LES) San Diego Chapter Meeting
BIOCOM Breakfast—Algae Biofuels
UC Technology Transfer Office Directors’ Meeting—Oakland, CA
September 08
Entrepreneurial Seminar—von Liebig Center
Tech Transfer at UCSD Seminar, Division of Biological Sciences*
Licensing Executive Society (LES) San Diego Chapter Meeting
CONNECT Technology Transfer Roundtable
Analytics in Marketing, Healthcare, Mobile Analytics, and Energy
UC Intellectual Property Managers—Santa Barbara, CA*
Institute for Conservation Research—Starting a Technology
Transfer Program*
UC Discovery Fellows—University Technology Transfer*
December 08
Connect with CONNECT
UCSD Business and Financial Services Purchasing Managers*
UC Technology Transfer Advisory Committee—Oakland, CA
Technology Licensing from TTO and Entrepreneur Viewpoints—
California Institute for Regenerative Medicine (CIRM)—Online Q&A with
California Stem Cell Researchers
Licensing Executive Society (LES) Workshop—University and
Industry Relations*
Cleantech Presentations—von Liebig Center
Engineering in Medicine (EngMed)
San Diego Daily Transcript Biotech Roundtable
New IP Models for Industry—UCSD External Relations*
San Diego State University, School of Business*
Entrepreneurial Seminar—von Liebig Center
Technology Transfer at UC San Diego—Skaggs School of Pharmacy and
Pharmaceutical Sciences*
Patents and Patent Searching—UCSD Staff Education and
Development Workshop*
CONNECT Most Innovative Product Awards and Program
UCSD Department of Bioengineering—Industry Advisory Board*
January 09
October 08
The Convergence of Nanotech and Cleantech Workshop—Palm Springs, CA*
Licensing Executive Society (LES)—Standards, Admissions, and
UCSD Industry Technology Transfer Advisory Committee Meeting*
Recertification Committee*
Patents and Patent Searching—UCSD Staff Education and
Development Workshop*
12
Innovators Roundtable Meeting—Physical Sciences Presentation*
Center for Magnetic Recording Research (CMRR) Review Meeting
CONNECT Technology Transfer Roundtable
BIOCOM Breakfast—Corporate Investing
UCSD Department of Bioengineering—Industry Advisory Board*
Representatives from the
Canadian government
and POLE (an economic
development agency) visit TTO.
[Left to right: Cheryl Rogers,
Charles Gauthier, Denise Lew
(TTO), Isabelle Genest, Yahya
Baby, and Claude Racine.]
February 09
June 09
Licensing Executive Society (LES) San Diego Chapter Meeting
Emerging Trends in Intellectual Property Valuation and Risk Analysis
Association of University Technology Managers Annual Meeting—Orlando, FL*
8th Annual SABPA Symposium on Biopharmaceuticals
TTO Overview and IP Process—Department of Chemistry and Biochemistry*
Licensing Executive Society (LES) San Diego Chapter Meeting— The New
Patents and Patent Searching—UCSD Staff Education and
Development Workshop*
UC Technology Transfer Office Directors’ Meeting—Oakland, CA
Era: Personalized Medicine
Global CONNECT—Southampton (UK)/San Diego Cleantech Conference
Genome Frontiers Symposium
Cancer Center Symposium—Moores UCSD Cancer Center
Research Expo—Jacobs School of Engineering
March 09
Innovators Roundtable Meeting—Life Science Technology Presentations*
Technology Licensing from the TTO and Entrepreneur Viewpoints—
San Diego State University, School of Business*
Visitors 2008–2009
San Diego Center for Molecular Agriculture Symposium
The Technology Transfer Office met with various organizations
throughout the year for benchmarking technology transfer
activities and to share best practices in technology transfer and
economic development.
April 09
July 08
UC San Diego Communications Directors*
Global CONNECT—Memorial Health System
UC Technology Transfer Advisory Committee—Oakland, CA
Kauffman Symposium—What Industry Wants from Universities
Material Transfer Agreements Workshop—Calit2*
Licensing Executive Society (LES) San Diego Chapter Meeting
May 09
September 08
University of Manchester, England
California Clean Innovation 2009 Conference*
November 08
BIOCOM Breakfast—Ernst & Young Industry Report
Global Leadership Institute (GLI)—Shanghai Huangpu District Delegation
Thinking Outside the Petri Dish—UCSD Biological Sciences
Student Association*
Patents and Patent Searching—UCSD Staff Education and
Development Workshop*
Entrepreneurial Seminar—von Liebig Center—Intellectual Property
Presentation*
Technology Transfer for the Rady Student—UCSD Rady School
of Management*
Association for Women in Science (AWIS)*
UC Intellectual Property Managers—Oakland, CA*
Licensing Executive Society (LES) San Diego Chapter Meeting—The Future
of Biotech: How to Succeed in a Time of Change
UC San Diego Salute to Innovation Program and Reception*
BIO 2009 International Convention—Atlanta, GA
December 08
POLE Quebec Economic Development Agency, Canada
Osaka University, Japan
January 09
Jiangsu Province Biotechnology District, China
March 09
Japan Patent Office
University of Melbourne, Australia
June 09
A*STAR and Exploit, Singapore
*TTO staff presented or actively participated.
13
Technology Transfer Office
University of California, San Diego | 9500 Gilman Drive # 0910 | La Jolla, CA 92093-0910
(858) 534-5815 | invent.ucsd.edu
0910-124